Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816165 · ClinicalTrials.gov registry record · Phase 3
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
A Phase 3 study of Type 1 Diabetes, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01816165 is a Phase 3 study of Type 1 Diabetes that has completed, run by University of Colorado, Denver. The registered enrollment target is 28 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01816165, a Phase 3 study of Type 1 Diabetes, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of intervention. The hypothesis of the study is that isolated fatty acid lowering with acipimox will improve insulin action and blood vessel function and have the benefit of reducing mitochondrial oxidant generation and improving mitochondrial function in T1D. Targeting IR through fatty acid lowering is a novel approach to T1D treatment that may significantly improve current management of TID and of cardiovascular disease (CVD) risk in this high risk population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acipimox
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816165
The ClinicalTrials.gov registry entry for NCT01816165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01816165 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01816165 about?
NCT01816165 is a clinical study titled "Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes". Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of intervention. The hypothesis of the study is that isolated fatty acid lowering w...
What is the current status of trial NCT01816165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2011-06. Estimated completion is 2015-06-24.
What conditions does trial NCT01816165 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT01816165?
The interventions under investigation include: Placebo (DRUG), Acipimox (DRUG).
Who is sponsoring clinical trial NCT01816165?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01816165 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
RECRUITING · Phase 3
-
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
ACTIVE NOT RECRUITING · Phase 3
-
Liraglutide in Adolescents With Type 1 Diabetes
COMPLETED · Phase 3
-
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.